1. Adelaide Research & Scholarship

Browsing "Pharmacology" by Title

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 132 to 151 of 918 < previous   next >
PreviewIssue DateTitleAuthor(s)
2009Buccal micronucleus cytome assayThomas, P.; Holland, N.; Bolognesi, C.; Kirsch-Volders, M.; Bonassi, S.; Zeiger, E.; Knasmueller, S.; Fenech, M.
2002Buprenorphine for the management of opioid withdrawalGowing, L.; Ali, R.; White, J.
2009Buprenorphine for the management of opioid withdrawalGowing, L.; Ali, R.; White, J.; Gowing, L.
2019Buprenorphine maintenance subjects are hyperalgesic and have no antinociceptive response to a very high morphine doseAthanasos, P.; Ling, W.; Bochner, F.; White, J.M.; Somogyi, A.A.
2003Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patientsMattick, R.; Ali, R.; White, J.; O'Brien, S.; Wolk, S.; Danz, C.
2003Buprenorphine versus methadone maintenance: a cost-effectiveness analysisDoran, C.; Shanahan, M.; Mattick, R.; Ali, R.; White, J.; Bell, J.
2006Cannabinoid 1 (CB1) receptors coupled to cholinergic motorneurones inhibit neurogenic circular muscle contractility in the human colonHinds, N.; Ullrich, K.; Smid, S.
2013Cannabinoid CB2 receptor activation attenuates cytokine-evoked mucosal damage in a human colonic explant model without changing epithelial permeabilityHarvey, B.; Nicotra, L.; Vu, M.; Smid, S.
2014Cannabinoid effects on β amyloid fibril and aggregate formation, neuronal and microglial-activated neurotoxicity in vitroJanefjord, E.; Maag, J.; Harvey, B.; Smid, S.
2009Cannabis and benzodiazepines as determinants of methadone trough plasma concentration variability in maintenance treatment: a transnational studyHallinan, R.; Crettol, S.; Agho, K.; Attia, J.; Besson, J.; Croquette-Krokar, M.; Hammig, R.; Deglon, J.; Byrne, A.; Ray, J.; Somogyi, A.; Eap, C.
2007Carboxylic acid drug-induced DNA nicking in HEK293 cells expressing human UDP-glucuronosyltransferases: Role of acyl glucuronide metabolites and glycation pathwaysSouthwood, H.; DeGraaf, Y.; MacKenzie, P.; Miners, J.; Burcham, P.; Sallustio, B.
2000Cardiovascular adverse effects of antipsychotic drugsBuckley, N.; Sanders, P.
1999Cardiovascular changes during morphine administration and spontaneous withdrawal in the rat.Chan, R.; Irvine, R.; White, J.
2004Cardiovascular responses to orthostatic and other stressors in men and women are independent of sexKelly, D.; Scroop, G.; Tonkin, A.; Thornton, A.
2010Caveat anicula! Beware of quiet little old ladies Demographic features, pharmacotherapy, readmissions and survival in a 10-year cohort of patients with heart failure and preserved systolic functionWong, T.; Clark, R.; Dundon, B.; Philpott, A.; Molaee, P.; Shakib, S.
2007CB1-independent inhibition of dopamine transporter activity by cannabinoids in mouse dorsal striatumPrice, D.; Owens, W.; Gould, G.; Frazer, A.; Roberts, J.; Daws, L.; Giuffrida, A.
2020CDK12: a potential therapeutic target in cancerEmadi, F.; Teo, T.; Rahaman, M.H.; Wang, S.
2006CEDIA (R) mycophenolic acid assay compared with HPLC-UV in specimens from transplant recipientsWestley, I.; Ray, J.; Morris, R.
2005CEDIAÒ sirolimus assay compared with HPLC-MS/MS and HPLC-UV in transplant recipient specimensWestley, I.; Morris, R.; Taylor, P.; Salm, P.; James, M.
2001Cell-free protein synthesis inhibition assay for the cyanobacterial toxin cylindrospermopsinFroscio, S.; Humpage, A.; Burcham, P.; Falconer, I.
Showing results 132 to 151 of 918 < previous   next >